A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More
AMLN
Recent Articles
Q2: Second Verse, Just Like the First — Monday’s IP Market Recap
Second-quarter trading picks up where Q1 left off -- by advancing smartly on the first day of trading. More
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More
Amylin Perks Up on Rejection — Wednesday’s IP Market Recap
A spurned bid from Bristol-Myers Squibb sends AMLN up 54% on speculation that other offers will roll in. More
‘Spam’ Linked to Diabetes in Native Americans
A new study raises questions about processed meat intake among Native Americans living on reservations and the development of diabetes. More
